Drug:Cisplatin
DrugConcurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
Other names: CDDP Drug
NCT Number: NCT06492460
The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 3
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The main objective of the trial was to evaluate whether the 3-year failure-free survival (FFS) rate in patients with high-risk head and neck squamous cell carcinoma treated with adjuvant radiotherapy and 2 courses of concurrent cisplatin chemotherapy after surgery was no less than 10% compared with 3 courses of concurrent cisplatin chemotherapy. The secondary objective was to evaluate efficacy and toxicity of 2 courses of concurrent cisplatin chemotherapy (100mg/m2, days 1 and 22) during adjuvant intensity-modulated radiation therapy will be compared with 3 courses of concurrent cisplatin chemotherapy (100mg/m2, days 1, 22 and 43).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
A. The pathological type is head and neck squamous cell carcinoma
B. Radical surgery has been performed with high risk factors (one of below)
C. No evidence of distant metastasis (M0).
D. Functional status: Karnofsky scale (KPS) > 70.
E. Normal bone marrow function:
G. Normal liver function:
H. Normal renal function: creatinine clearance > 60 ml/min.
I. Patients must be informed of the basic contents of this study and sign informed consent.
Exclusion criteria
A. Age >70 years or <18 years.
B. Treatment is palliative.
C. Previous chemotherapy (except induction chemotherapy prior to surgery).
D. Previous radiation therapy.
E. Women who are pregnant or breastfeeding
F. Previous history of malignant tumor.
G. With other serious medical conditions that may pose a greater risk or affect compliance with the test. Examples include:
Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
Other names: CDDP Drug
Time frame: 3 years
calculated from enrolment to the date of locoregional recurrence,distant metastasis,or death from any cause, whichever occurred first.
Time frame: 3 years
calculated from enrolment to the date of death from any cause.
Time frame: 3 years
calculated from enrolment to the date of first distant metastasis.
Time frame: 3 years
calculated from enrolment to the date of locoregional persistence or 1st locoregional recurrence.
Time frame: 3 years
The change of QoL from randomization to the start of radiotherapy,the end of radiotherapy,13-16 weeks after radiotherapy,2 years and 3 years after randomization. The EORTC QoL questionnaire-C30(EORTC quality of life questionnaire-C30#version 3.0 will be used. This questionnaire comprises 30 questions,24 of which are aggregated into nine multi- question scales,that is,five functioning scales (e.g.,physical),three symptom scales (e.g.,fatigue)and one global health status scale. The remaining six single-question (e.g.,dyspnoea)scales assess symptoms. These 15 scales will be scored according to the official Scoring Manual.
Contact information is provided by the study sponsor or research team.
Sun Yat-sen University
Other
A Multicenter, Randomized Controlled, Non-inferior Phase 3 Clinical Trial of 2 Courses of Concurrent Cisplatin Chemoradiotherapy Versus 3 Courses After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04389632
Adenocarcinoma Of Esophagus, Adnexal Diseases
Anchorage, Alaska, United States
View Trial DetailsNCT06385080
Carcinoma, Carcinoma, Squamous Cell
La Jolla, California, United States
View Trial DetailsNCT07276399
Carcinoma, Carcinoma, Squamous Cell
Chandler, Arizona, United States
View Trial DetailsNCT07219212
Carcinoma, Carcinoma, Squamous Cell
Birmingham, Alabama, United States
View Trial Details